Aelix Therapeutics
Aelix Therapeutics develops therapies for HIV as a spinout from Barcelona's HIVACAT Research Center. The company uses polynucleotide sequences from T-cells derived from HIV patients with naturally low viral loads, converted into DNA and delivered as a vaccine using a modified Ankara virus (MVA) as a vector. The vaccine has completed a Phase 1 trial. Founded in 2015 in Barcelona, Spain, the company has raised $12.6M…
Funding snapshot
About
Aelix Therapeutics develops therapies for HIV as a spinout from Barcelona's HIVACAT Research Center. The company uses polynucleotide sequences from T-cells derived from HIV patients with naturally low viral loads, converted into DNA and delivered as a vaccine using a modified Ankara virus (MVA) as a vector. The vaccine has completed a Phase 1 trial. Founded in 2015 in Barcelona, Spain, the company has raised $12.6M in Series A funding from investors including Ysios Capital and Johnson & Johnson Innovation. It is a spinout from Barcelona's HIVACAT Research Center. The company plans to use polynucleotide sequences from T-cells derived from a cohort of HIV patients with naturally low viral loads.
Business model
Infectious Diseases > Drugs > Viral > HIV,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.